CAJ | 학술논문

目的：观察并分析伊立替康或奥沙利铂联合氟尿嘧啶类药物一线治疗晚期胃癌的疗效。方法筛选既往应用伊立替康联合氟尿嘧啶类药物一线治疗的晚期胃癌患者20例纳入A组，应用奥沙利铂联合氟尿嘧啶治疗的22例患者纳入B组，比较两组的一般资料、疗程、预后与不良反应发生情况。结果 A、B两组患者年龄、分化情况、转移部位、Kamofsky评分的差异无统计学意义（P>0.05）；A组总周期数、最长周期数和平均周期数均低于B组，中位周期数高于B组，差异无统计学意义（P>0.05）；A组疗效优于B组，差异具有统计学意义（P<0.05）；A组中位进展时间和中位生存期均大于B组，差异具有统计学意义（P<0.05）。两组各系统不良反应与毒性分级分布的差异无统计学意义（P>0.05）。结论氟尿嘧啶联合伊立替康治疗晚期胃癌的疗效优于联合奥沙利铂，患者生存期相对更长，肿瘤再次进展时间更晚，且不会增加不良反应的发生风险，多数患者可耐受。
목적：관찰병분석이립체강혹오사리박연합불뇨밀정류약물일선치료만기위암적료효。방법사선기왕응용이립체강연합불뇨밀정류약물일선치료적만기위암환자20례납입A조，응용오사리박연합불뇨밀정치료적22례환자납입B조，비교량조적일반자료、료정、예후여불량반응발생정황。결과 A、B량조환자년령、분화정황、전이부위、Kamofsky평분적차이무통계학의의（P>0.05）；A조총주기수、최장주기수화평균주기수균저우B조，중위주기수고우B조，차이무통계학의의（P>0.05）；A조료효우우B조，차이구유통계학의의（P<0.05）；A조중위진전시간화중위생존기균대우B조，차이구유통계학의의（P<0.05）。량조각계통불량반응여독성분급분포적차이무통계학의의（P>0.05）。결론불뇨밀정연합이립체강치료만기위암적료효우우연합오사리박，환자생존기상대경장，종류재차진전시간경만，차불회증가불량반응적발생풍험，다수환자가내수。
ObjectiveToevaluatetheefficacyofirinotecanoroxaliplatincombinedwithfluorouracildrugsforpatients with advanced gastric cancer. Methods Select 20 cases of advanced gastric cancer patients who had irinotecan plus fluor-ouracil medicament in the past into the group A, and other 22 cases of advanced gastric cancer patients who previously had oxaliplatin combined with fluorouracil into the group B. Compare the general information, treatment, prognosis and adverse reaction conditions between the two groups. Results Group A and B had no statistical differences in age, tumor differentia-tion, tumor metastatic sites, and Kamofsky score (P>0.05). The total cycles, the longest cycles and the average cycles of patients all were lower in group A than in group B. The median cycle number was higher in group A than in group B, but the difference had no statistical significance (P>0.05). The group A showed better curative effect than group B, and the dif-ference had statistical significance (P<0.05). The group A also had longer median time to progression and median survival time than group B, with statistically significant differences (P<0.05). The adverse reaction and distribution of toxicity de-grees had no significant differences between the two groups (P>0.05). Conclusion Fluorouracil and irinotecan in combina-tion had better curative effect than fluorouracil combined with oxaliplatin on advanced gastric cancer patients and did not increase the risk of adverse reactions. Patients treated by fluorouracil and irinotecan in combination had longer survival time and longer tumor free-progressive time. Most patients can tolerate the adverse reactions.